PE20130775A1 - Antagonistas no competitivos de receptores nicotinicos - Google Patents

Antagonistas no competitivos de receptores nicotinicos

Info

Publication number
PE20130775A1
PE20130775A1 PE2012002210A PE2012002210A PE20130775A1 PE 20130775 A1 PE20130775 A1 PE 20130775A1 PE 2012002210 A PE2012002210 A PE 2012002210A PE 2012002210 A PE2012002210 A PE 2012002210A PE 20130775 A1 PE20130775 A1 PE 20130775A1
Authority
PE
Peru
Prior art keywords
alkyl
bicycle
hydrochloride
amine
compounds
Prior art date
Application number
PE2012002210A
Other languages
English (en)
Inventor
Srinivasa Rao Akireddy
Balwinder Singh Bhatti
Ronald Joseph
Matt S Melvin
Jason Speake
Yunde Xiao
Daniel Yohannes
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PE20130775A1 publication Critical patent/PE20130775A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS ANTAGONISTAS NO COMPETITIVOS DE RECEPTORES NICOTINICOS DE FORMULA (I) DONDE: R1 Y R2 INDIVIDUALMENTE ES H, ALQUILO DE C1-C6, ALQUILO C1-C6 SUSTITUIDO CON ARILO, ENTRE OTROS; R3 ES H, ALQUILO DE C1-C6, R7 ES INDIVIDUALMENTE H, ALQUILO DE C1-C6, O ALCOXI DE C1-C6; L1 ES UN CONECTOR SELECCIONADO DEL GRUPO FORMADO POR CR8R9, CR8R9CR10R11, O; R8,R9,R10,R11 ES H, ALQUILO C1-C6 , L2 ES UN CONECTOR SELECCIONADO DEL GRUPO FORMADO POR CH2, CH2CH2, CH2CH2CH2 Y CH2CH2CH2CH2. SON COMPUESTOS PREFERIDOS: CLORHIDRATO DE N,3-DIMETILESPIR[BICICLO[2.2.1]HEPTANO-2,1´-CICLOPROPAN]-3-AMINA; CLORHIDRATO DE N, 3-DIMETILESPIRO[BICICLO]OCT[5]ENO-2,1´-CICLOPENTAN]-3-AMINA Y CLORHIDRATO DE N,3-DIMETILESPIRO[BICICLO[2.2.2]OCTANO-2,1´-CICLOPENTAN]-3-AMINA, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN ELTRATAMIENTO O PREVENCION DE UNA ENFERMEDAD MEDIADA POR UN RECEPTOR NICOTINICO NEURONAL.
PE2012002210A 2010-05-27 2011-05-24 Antagonistas no competitivos de receptores nicotinicos PE20130775A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34902710P 2010-05-27 2010-05-27
US37560610P 2010-08-20 2010-08-20

Publications (1)

Publication Number Publication Date
PE20130775A1 true PE20130775A1 (es) 2013-07-21

Family

ID=44462072

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002210A PE20130775A1 (es) 2010-05-27 2011-05-24 Antagonistas no competitivos de receptores nicotinicos

Country Status (22)

Country Link
US (6) US8809397B2 (es)
EP (1) EP2576496B1 (es)
JP (2) JP5893610B2 (es)
KR (1) KR101856046B1 (es)
CN (2) CN102918021B (es)
AU (1) AU2011258553B2 (es)
BR (1) BR112012030004A2 (es)
CA (1) CA2799203C (es)
CL (1) CL2012003274A1 (es)
CO (1) CO6680603A2 (es)
ES (1) ES2623373T3 (es)
IL (2) IL223060A (es)
MX (1) MX337106B (es)
NZ (1) NZ603966A (es)
PE (1) PE20130775A1 (es)
PL (1) PL2576496T3 (es)
RU (2) RU2582339C2 (es)
SG (1) SG185643A1 (es)
TW (1) TW201200129A (es)
UY (1) UY33409A (es)
WO (2) WO2011149862A1 (es)
ZA (1) ZA201208836B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102918021B (zh) * 2010-05-27 2015-02-11 塔加西普特公司 烟碱受体非竞争性拮抗剂
BR112014010719A2 (pt) * 2011-11-03 2017-05-02 Targacept Inc moduladores não competitivos de receptor nicotínico
WO2013142162A1 (en) * 2012-03-23 2013-09-26 Targacept, Inc. Method of treating bladder disorders
US11840495B2 (en) 2020-12-23 2023-12-12 The Broad Institute, Inc. Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2931805A (en) * 1958-11-10 1960-04-05 Smith Kline French Lab Spiro [bicyclo [2. 2. 1] heptane-2, 2'-alkylenimines]
US3290215A (en) * 1963-10-29 1966-12-06 Du Pont Use of methanoindanamines as antiviral agents
US3317387A (en) * 1964-05-25 1967-05-02 Du Pont Method of reducing the severity of influenza virus infections
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JP2802486B2 (ja) 1995-11-30 1998-09-24 花王株式会社 トリシクロカルボン酸エステルおよびその製造法
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
CN2284883Y (zh) 1996-07-12 1998-06-24 陈智 纯滚活齿传动
WO1998011882A1 (en) * 1996-09-18 1998-03-26 Codon Pharmaceuticals, Inc. Pharmaceutical compositions and methods
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
DE69939498D1 (de) 1998-12-16 2008-10-16 Univ South Florida Exo-S-Mecamylamin-Formulierung
TW200306189A (en) * 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
EP1499618B1 (en) * 2002-04-18 2010-10-13 AstraZeneca AB Furyl compounds
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CA2537185A1 (en) 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
US20070270458A1 (en) 2003-12-22 2007-11-22 Glen Ernst Nicotinic Acetylcholine Receptor Ligands
NZ552792A (en) 2004-08-20 2009-12-24 Targacept Inc The use of N-aryl diazaspiracyclic compounds in the treatment of addiction
AR054816A1 (es) * 2005-07-13 2007-07-18 Banyu Pharma Co Ltd Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos
TW200845977A (en) * 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
WO2009039181A2 (en) * 2007-09-17 2009-03-26 State Of Oregon Acting By & Through The State Board Of Higher Education On Behalf Of Or. State Univ. Sulfonamide-based organocatalysts and method for their use
CN101959888A (zh) 2008-03-05 2011-01-26 塔加西普特公司 二氮杂双环烷烃的烟碱乙酰胆碱受体亚型的选择性酰胺
CN102918021B (zh) * 2010-05-27 2015-02-11 塔加西普特公司 烟碱受体非竞争性拮抗剂
WO2013026852A2 (en) * 2011-08-22 2013-02-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Derivatives of mecamylamine

Also Published As

Publication number Publication date
CN102918021B (zh) 2015-02-11
EP2576496B1 (en) 2017-03-08
US20170071878A1 (en) 2017-03-16
CA2799203C (en) 2018-05-08
IL223060A0 (en) 2013-02-03
ES2623373T3 (es) 2017-07-11
CA2799203A1 (en) 2011-12-01
US20140315877A1 (en) 2014-10-23
MX337106B (es) 2016-02-12
US10716770B2 (en) 2020-07-21
AU2011258553A1 (en) 2013-01-10
UY33409A (es) 2013-01-03
US10258582B2 (en) 2019-04-16
US20180271806A1 (en) 2018-09-27
WO2011149859A1 (en) 2011-12-01
ZA201208836B (en) 2013-07-31
IL223060A (en) 2015-10-29
CN104557568A (zh) 2015-04-29
EP2576496A1 (en) 2013-04-10
WO2011149862A1 (en) 2011-12-01
JP2013528178A (ja) 2013-07-08
NZ603966A (en) 2015-03-27
SG185643A1 (en) 2012-12-28
AU2011258553B2 (en) 2014-08-14
CL2012003274A1 (es) 2013-05-24
KR20130075748A (ko) 2013-07-05
US20160008323A1 (en) 2016-01-14
US20190254991A1 (en) 2019-08-22
TW201200129A (en) 2012-01-01
PL2576496T3 (pl) 2017-08-31
RU2016111390A (ru) 2017-10-04
MX2012013618A (es) 2013-02-01
US20130203860A1 (en) 2013-08-08
US8809397B2 (en) 2014-08-19
CN104557568B (zh) 2017-04-12
BR112012030004A2 (pt) 2016-08-02
JP5893610B2 (ja) 2016-03-23
US9532974B2 (en) 2017-01-03
JP2016172717A (ja) 2016-09-29
KR101856046B1 (ko) 2018-06-25
RU2012157224A (ru) 2014-07-10
CN102918021A (zh) 2013-02-06
CO6680603A2 (es) 2013-05-31
IL241743A0 (en) 2015-11-30
RU2582339C2 (ru) 2016-04-27

Similar Documents

Publication Publication Date Title
MY161199A (en) Fused tricyclic dual inhibitors of cdk 4/6 and flt3
AR047992A1 (es) Diaminopirimidinas como antagonistas de p2x3 y p2x2/3
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
MX2012004848A (es) Compuestos heterociclicos triciclicos.
CY1117792T1 (el) Ανταγωνιστες toy trpv4
AR080688A1 (es) Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
ECSP11011189A (es) Moduladores de los receptores tipo toll
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas
EA200970928A1 (ru) Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения
AR083831A1 (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
EA201100409A1 (ru) Замещенные производные триазолопиридазина
CR8094A (es) Derivados de imidazol antagonistas del receptor de glutamato
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.
PE20121066A1 (es) Derivados de diazahomoadamantano y metodos para usarlos
MY152805A (en) Benzazepine derivatives useful as vasopressin antagonists
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
ATE473221T1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
CY1117261T1 (el) [4-(5-αμινομεθυλο-2-φθορο-φαινυλο)-πιπεριδιν-1-υλο]-[7-φθορο-1-(2-μεθοξυ-αιθυλο)-4τριφθορο μεθοξυ-1η-ινδολ-3-υλο]-μεθανονη ως αναστολεας τρυπτασης maστοκυτταρων
CO6430439A2 (es) Agonistas del receptor de esfingosina -1- fosfato
PE20130775A1 (es) Antagonistas no competitivos de receptores nicotinicos
ECSP099441A (es) Nuevos intermediarios y procesos útiles en la preparación de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
CY1117826T1 (el) Ενωσεις μορφiνανης
PA8561501A1 (es) Lactamas como antagonistas de taquiquininas

Legal Events

Date Code Title Description
FC Refusal